国际皮肤性病学杂志    0  (): 279-281   ISSN: 2096-5540  CN: 32-1880/R   经皮肤外用基因免疫接种:疫苗研究的新策略 谢杨新, 廖文俊 第四军医大学西京医院皮肤科, 西安710032 收稿日期 2005-01-06  修回日期 null  网络版发布日期 null 参考文献  [1] Kane A, Lloyd J, Zaffran M, et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world:model-based regional estimates. Bull World Health Organ, 1999, 77:801-807. [2] Uchi H, Terao H, Koga T, et al. Cytokines and chemokines in the epidermis. J Dermatol Sci, 2000, 24(Suppl 1):S29-S38. [3] Debenedictis C, Joubeh S, Zhang G, et al. Immune functions of the skin. Clin Dermatol, 2001, 19:573-585. [4] Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci, 2001, 14:101-114. [5] Wu H, Ramachandran C, Bielinska AU, et al. Topical transfection using plasmid DNA in a water-in-oil nanoemulsion. Int J Pharm,2001, 221:23-34. [6] Choi MJ, Maibach HI. Topical vaccination of DNA antigens:topical delivery of DNA antigens. Skin Pharmacol Appl Skin Physiol, 2003,16:271-282. [7] Alexander MY, Akhurst RJ. Liposome-medicated gene transfer and expression via the skin. Hum Mol Genet, 1995, 4:2279-2285. [8] Alexander MY, Bidichandani S, Robinson C, et al. Physical methods of gene delivery using keratinocytes as a target for somatic cell gene therapy. Gene Ther, 1994,1(Suppl 1):S57. [9] Li L, Hoffman RM. The feasibility of targeted selective gene therapy of the hair follicle. Nat Med, 1995, 1:705-706. [10] Niemiec SM, Latta JM, Ramachandran C, et al. Perifollicular transgenic expression of human interleukin-1 receptor antagonist protein following topical application of novel liposome-plasmid DNA formulations in vivo. J Pharm Sci, 1997, 86:701-708. [11] Tang DC, Shi Z, Curiel DT. Vaccination onto bare skin. Nature,1997, 388:729-730. [12] Shi Z, Zeng M, Yang G, et al. Protection against tetanus by needlefree inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol, 2001, 75:11474-11482. [13] Cui Z, Mumper RJ. Chitosan-based nanoparticles for topical genetic immunization. J Control Release, 2001, 75:409-419. [14] Cui Z, Fountain W, Clark M, et al. Novel ethanol-in-fluorocarbon microemulsions for topical genetic immunization. Pharm Res, 2003,20:16-23. [15] Scharton-Kersten T, Yu J, Vassell R,et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun, 2000, 68:5306-5313. [16] Watabe S, Xin KQ, Ihata A,et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine,2001, 19:4434- 4444. [17] Liu LJ, Watabe S, Yang J, et al. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigenspecific immune responses. Vaccine, 2001, 20:42-48. [18] Bramson J, Dayball K, Evelegh C, et al. Enabling topical immunization via microporation:a novel method for pain-free and needlefree delivery of adenovirus-based vaccines. Gene Ther, 2003, 10:251-260. [19] Kang M J, Kim CK, Kim MY, et al. Skin permeation, biodistribution,and expression of topically applied plasmid DNA. J Gene Med,2004, 6:1238-1246. 通讯作者: